Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | PRKACA | P17612 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 2/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.42 |
| ▸ | BCL6 | P41182 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 2/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7635158 | 0.77 | ROCK1 (0.40) | HSP90AA1AURKAPRKACAADORA2AALOX5AP | |
| Diaminopyrimidine SCHEMBL2745437 | 0.76 | TSHR (0.53) | HSP90AA1AURKAPRKACAADORA2AROCK1 | |
| SCHEMBL16369913 | 0.74 | HTR6 (0.59) | HTR6KDM4EALDH1A1PKMAKR1B1 | |
| SCHEMBL27849935 | 0.73 | ROCK1 (0.40) | HSP90AA1AURKAPRKACAADORA2AALOX5AP | |
| SCHEMBL28938658 | 0.73 | ROCK1 (0.45) | HSP90AA1AURKAPRKACAADORA2AALOX5AP | |
| SCHEMBL1573626 | 0.71 | KDM4E (0.72) | HTR6KDM4EALDH1A1PKMAKR1B1 | |
| SCHEMBL28021699 | 0.70 | HTR6 (0.46) | HTR6KDM4EALDH1A1MAPTAKT1 | |
| SCHEMBL11523904 | 0.69 | AGTR1 (0.49) | ALOX5APHTR6KDM4EAKR1B1MAPT | |
| SCHEMBL29065907 | 0.69 | TSHR (0.59) | HTR6BCL6KDM4EALDH1A1MAPT | |
| SCHEMBL6951196 | 0.68 | HTR6 (0.45) | HTR6KDM4EALDH1A1PKMAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097587-B2 | IGF-I protein variants for treating IGFBP-1-related disorders | GENENTECH, INC. (US) | 2012-01-17 | — | — | US | claimed |
| US-7105167-B2 | Methods for treating clinical manifestations of GH/GF axis dysregulation by administration of an IGF-I variant | GENENTECH, INC. (US) | 2006-09-12 | — | — | US | claimed |
| US-8097587-B2 | IGF-I protein variants for treating IGFBP-1-related disorders | GENENTECH, INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-20110003746-A1 | Protein variants | DUBAQUIE YVES | 2011-01-06 | — | — | US | disclosed |
| EP-0827408-B1 | METHOD OF ADMINISTRATION OF IGF-I | GENENTECH INC (US) | 2006-10-25 | — | — | EP | disclosed |
| US-7105167-B2 | Methods for treating clinical manifestations of GH/GF axis dysregulation by administration of an IGF-I variant | GENENTECH, INC. (US) | 2006-09-12 | — | — | US | disclosed |
| EP-1506972-A1 | Insulin-like growth factor (IGF) I mutant variants | Genentech Inc. (US) | 2005-02-16 | — | — | EP | disclosed |
| EP-1141014-B1 | INSULIN-LIKE GROWTH FACTOR (IGF) I MUTANT VARIANT | GENENTECH INC (US) | 2004-12-08 | — | — | EP | disclosed |
| US-6653287-B1 | Modulating cardiac function; heart disorders | GENENTECH, INC. | 2003-11-25 | — | — | US | disclosed |
| EP-0830143-B1 | USE OF LEUKEMIA INHIBITORY FACTOR AND ENDOTHELIN ANTAGONISTS | GENENTECH INC (US) | 2003-03-05 | — | — | EP | disclosed |
| EP-1287832-A2 | Use of leukemia inhibitory factor antagonist | GENENTECH, INC. (US) | 2003-03-05 | — | — | EP | disclosed |
| US-5985830-A | Use of IGF-I for the treatment of kidney disorders | DALHOUSIE UNIVERSITY (CA) | 1999-11-16 | — | — | US | disclosed |
| WO-1999011271-A1 | USE OF POLYCYCLIC STEROID COMPOUNDS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF CYSTIC KIDNEY DISEASES, VASCULAR INFARCTION, UREMIA AND RELATED CONDITIONS | DALHOUSIE UNIVERSITY (CA) | 1999-03-11 | — | — | WO | disclosed |
| US-5837241-A | ADMINISTERING ANTIBODY TO PREVENT HYPERTROPHY | GENENTECH, INC. (US) | 1998-11-17 | — | — | US | disclosed |
| US-5741776-A | ADMINISTERING FOR A PERIOD OF TIME THEN DISCONTINUING ADMINISTRATION FOR AN EQUAL OR LESS PERIOD OF TIME; REPEATING TO GAIN DESIRED BIOLOGICAL RESPONSE | GENENTECH, INC. (US) | 1998-04-21 | — | — | US | disclosed |
| WO-1998011913-A1 | USE OF IGF-I FOR THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE AND RELATED INDICATIONS | DALHOUSIE UNIVERSITY (CA) | 1998-03-26 | — | — | WO | disclosed |
| EP-0830143-A1 | USE OF LEUKEMIA INHIBITORY FACTOR AND ENDOTHELIN ANTAGONISTS | GENENTECH, INC. (US) | 1998-03-25 | — | — | EP | disclosed |
| US-5573762-A | Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy | GENENTECH, INC. (US) | 1996-11-12 | — | — | US | disclosed |
| WO-1996033740-A1 | USE OF LEUKEMIA INHIBITORY FACTOR AND ENDOTHELIN ANTAGONISTS | GENENTECH, INC. (US) | 1996-10-31 | — | — | WO | disclosed |
| US-5565428-A | INTERMITTENT DOSING | GENENTECH, INC. (US) | 1996-10-15 | — | — | US | disclosed |